expr:content='data:blog.blogId' itemprop='blogId'/> CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 06 August 2018

CS OPENING BELL:

NIFTY SPOT UP 61@11422

SENSEX SPOT UP 237 @37793

BANK NIFTY FUTURES SPOT UP 208@ 27984

                                                                     HAPPY TRADING!

CS NIFTY FUTURES (JUNE ) OVERVIEW

TREND BEARISH

RES2: 11500

RES 1:11440

SUP1:11260

SUP2:10910

CS BANK NIFTY FUTURES (JUNE ) OVERVIEW

TREND BULLISH

RES 2: 28100

RES 1: 27880

SUP1: 27400

SUP2: 27200

visit us: www.capitalstars.com/

call us:

9977499927

7440449744

Get more details here:-

Mcx tips,  Intraday stock tips, Financial Advisory Company,Share Market Company

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 02 August 2018

CS OPENING BELL:

NIFTY SPOT DOWN 32 @11313

SENSEX SPOT DOWN 119 @37402

BANK NIFTY FUTURES SPOT DOWN 182@ 27480

                                                                                                    HAPPY TRADING!

CS NIFTY FUTURES (JUNE ) OVERVIEW

TREND BEARISH

RES2: 11550

RES 1:11480

SUP1:11280

SUP2:10910

CS BANK NIFTY FUTURES (JUNE ) OVERVIEW

TREND BULLISH

RES 2: 28100

RES 1: 27880

SUP1: 27650

SUP2: 27400

visit us: www.capitalstars.com/

call us:

9977499927

7440449744

Get more details here:-

Mcx tips,  Intraday stock tips, Financial Advisory Company,Share Market Company

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 30 july 2018

CS OPENING BELL:

NIFTY SPOT UP 25@11304

SENSEX SPOT UP 89@37426

BANK NIFTY FUTURES SPOT UP 39@ 27678

                                                                                                          HAPPY TRADING!

                                                                                                     www.capitalstars.com                                 

CS NIFTY FUTURES (JUNE ) OVERVIEW

TREND BEARISH

RES2: 11450

RES 1:11300

SUP1:11200

SUP2:10910

CS BANK NIFTY FUTURES (JUNE ) OVERVIEW

TREND BULLISH

RES 2: 27980

RES 1: 27800

SUP1: 27650

SUP2: 27400

visit us: www.capitalstars.com/

call us:

9977499927

7440449744

Get more details here:-

Mcx tips,  Intraday stock tips, Financial Advisory Company

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 27 july 2018

CS OPENING BELL:

NIFTY SPOT UP 58@11226

SENSEX SPOT UP 199@37184

BANK NIFTY FUTURES SPOT UP 73@ 27509

                                                                                                HAPPY TRADING!

                                                                                             www.capitalstars.com                                 

CS NIFTY FUTURES (JUNE ) OVERVIEW

TREND BEARISH

RES2: 11240

RES 1:11185

SUP1:11100

SUP2:10910

CS BANK NIFTY FUTURES (JUNE ) OVERVIEW

TREND BULLISH

RES 2: 27880

RES 1: 27600

SUP1: 27200

SUP2: 26900

visit us: www.capitalstars.com/

call us:

9977499927

7440449744

Get more details here:-

Mcx tips,  Intraday stock tips, Financial Advisory Company

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CAPITALSTARS:-CLOSING BELL

CS CLOSING BELL:

NIFTY SPOT UP 01@10948

SENSEX SPOT UP 26@ 36265

BANK NIFTY FUTURES DOWN 101@ 26781

                                                                                        HAPPY TRADING!!!!!!!!!!!

Call on:9977499927

 +917440449744

Get more details here:-

Mcx tips,  Intraday stock tips, Financial Advisory Company

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

* CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 10 JULY 2018

CS OPENING BELL:

NIFTY SPOT UP 59@ 10,912

SENSEX SPOT UP 204@ 36139

BANK NIFTY FUTURES SPOT UP 142@ 26,855

                                                                                                  HAPPY TRADING!

CS NIFTY FUTURES (JUNE ) OVERVIEW

TREND BEARISH

RES2: 11100

RES 1:10950

SUP1:10810

SUP2:10700 

CS BANK NIFTY FUTURES (JUNE ) OVERVIEW

TREND BEARISH

RES 2: 27100

RES 1: 26980

SUP1: 26600

SUP2: 26400

call on:9977499927

O731-6690000

Get more details here:-

Mcx tips,  Intraday stock tips, Financial Advisory Company

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

* CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

Sensex falls 239 pts, Nifty ends below 10,700; Rel Comm jumps 65%

Benchmark indices closed lower for the second consecutive session amid political turmoil in Italy.

The 30-share BSE Sensex declined 43.13 points to 34,906.11 and the 50-share NSE Nifty slipped 18.90 points to 10,614.40.

About 1,444 shares declined against 1,222 advancing shares on the BSE.

Nava Bharat Ventures, Info Edge, Torrent Power and Satin Creditcare gained up to 20 percent while Vakrangee, Just Dial, South Indian Bank and Adani Power fell up to 5 percent.

HEADLINES OF THE DAY

CRISIL stock price is locked at 20 percent upper circuit after 6.33 lakh equity shares (representing 0.9 percent of total equity) exchanged hands on the National Stock Exchange at Rs 1851.05 per share.

Hotel Leela Venture share price declined nearly 2 percent after the company reported net loss at Rs 15.8 crore.

Borosil Glass Works share price rallied 5 percent after March quarter profit shot up 66 percent year-on-year to Rs 14.8 crore.

Aban Offshore has increased its losses in the quarter ended March 2018 on the back of weak operating numbers.

Alkem Laboratories' March quarter consolidated profit fell sharply by 51.6 percent year-on-year to Rs 66.3 crore.

arksans Pharma has reported profit in the quarter ended March 2018. The company's Q4 net profit was at Rs 4.3 crore.

UPCOMING RESULTS: -   BOMBAY POTTERIE, REIL ELECTRIC, HIMALAYA FOOD,  BANARAS BEADS,

 visit us: www.capitalstars.com/

call on:9977499927

O731-6690000

Get more details here:-

Mcx tips,  Intraday stock tips, Financial Advisory Company

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

* CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

CAPITALSTARS NIFTY FUTURES & BANK NIFTY FUTURES OVERVIEWS 10 MAY 2018

CS OPENING BELL:

NIFTY SPOT UP 23 @ 10764

SENSEX UP 100 @ 35420

BANK NIFTY FUTURES UP 55  @ 26138

HAPPY TRADING!!!!!!!!!!!

CS NIFTY FUTURES (MAY ) OVERVIEW

TREND BEARISH

RES2: 10875

RES 1:10810

SUP1:10750

SUP2:10700

CS BANK NIFTY FUTURES (MAY ) OVERVIEW

TREND BEARISH

RES 2: 26350

RES 1: 26250

SUP1: 26050

SUP2: 25950

visit us: www.capitalstars.com/

call on:9977499927

O731-6690000

Get more details here:-

Mcx tips, Intraday stock tips 

* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

* CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

Capitalstars Updates: Top Corporate News :- 30 Jan 2018

Top Headlines Of The Day:- 30 Jan 2018

Jubilant receives ANDA approval for Clonidine Hydrochloride ER Tablets

KPIT and Birlasoft to come together to create two entities

Mylan and Biocon receive positive CHMP opinion for Insulin Glargine

Amber Enterprises lists at 38% premium to issue price

HCL Tech gets 5-year order from Cadent for IT Infra services

Jubilant receives ANDA approval for Clonidine Hydrochloride ER Tablets
Jubilant Life Sciences has announced that its material wholly owned subsidiary Jubilant Pharma Limited has received Abbreviated New Drug Application (ANDA) final approval for Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg. This is a generic version of Kapvay of Concordia. It is used for the treatment of attention deficit hyperactivity disorder (ADHD).
As on December 31, 2017, Jubilant had a total of 86 ANDAs for Oral Solids filed in the US of which 56 had been approved and 12 Injectable filings of which 10 had been approved. This is the eighth USFDA approval in FY18.

Clonidine Hydrochloride Extended-Release Tablets, 0.1 mg had annual sales of ~USD 66 million in the US as per IMS MAT Jun 2017. 

KPIT and Birlasoft to come together to create two entities
KPIT Technologies had informed the exchanges that its board had approved a draft composite scheme for amalgamation of Birlasoft (India) with KPIT. The second leg of the transaction would involve demerger of the engineering business of the company into KPIT Engineering Limited (KEL), a wholly owned subsidiary of the company and will be renamed as KPIT Technologies Limited.
According to the arrangement, shareholders of Birlasoft will receive 22 equity shares of the combined KPIT -Birlasoft for every nine equity shares of Birlasoft. the combined KPIT-Birlasoft will be engaged in the ITSS Business, and pursuant to the Proposed Demerger, KEL's shares will be listed and shareholders of combined KPIT-Birlasoft will receive one share of KEL for each share they hold in the combined KPIT-Birlasoft.

Mylan and Biocon receive positive CHMP opinion for Insulin Glargine
Biocon has announced that it, along with its partner Mylan, has received a positive opinion from Europen Medical Agency’s (EMA) - Committee for Medicinal Products for Human Use (CHMP) - for insulin Glargine. CHMP has also recommended approval to Insulin Glargine, which will be sold under brand Semglee.
There are ~60m people affected by diabetes in Europe with an increasing prevalence in the region. Insulin Glargine is a biosimilar, which will be available for commercialization once it receives EMA approval.
Biocon and Mylan are also awaiting approval for Insulin Glargine in Australia, Canada, and the US and are planned for key Emerging Markets.

Amber Enterprises lists at 38% premium to issue price
Amber Enterprises listed at a significant premium of 38% to its issue price of Rs855-859 and is currently trading at Rs1, 187.2.
The IPO offer consisted of Fresh Issue of 55.3 lakh shares (aggregating up to ~Rs475cr) at the upper end of the price band. It also includes an offer for sale of up to 14.6 lakh shares (Rs125cr) by the promoters. The issue proceeds will be used for pre-payment or repayment of borrowings (~Rs400cr) and for other general corporate purposes (~Rs75cr).

HCL Tech gets 5-year order from Cadent for IT Infra services
HCL Technologies (HCL) announced a five-year IT infrastructure services and application management contract with Cadent, the UK’s largest gas distribution network. The ground-breaking ‘cloud first’ multi-service deal will see HCL provide integrated public cloud hosting and SAP and Application Maintenance Services, including the migration of a significant applications portfolio to Amazon Web Services (AWS) public cloud. In addition, HCL will provide IT Service Management, Service Desk and Managed Workplace Services.
HCL will deliver these services to support Cadent’s business operations which distributes gas to 11 million homes and businesses in the North West, Midlands, East and South East of England. HCL will provide MWS support to approximately 4,500 staff; including 3,500 field based-engineers who work across the company’s 65 regional depots.

MCX Tips,  Intraday Stock Tips ,  Equity Tips  , Free Trading Tips , Sebi Regsitred Advisory Company , Capitalstars Video Gallery

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

Capitalstars Updates: Top Corporate News :- 29 Jan 2018

Top Headlines Of The Day :- 29 Jan 2018

Avenue Supermarts Ltd (DMart), up 5% after announcing Q3FY18 results, PAT up 65.8% yoy
Cipla, Aurobindo and Strides Shasun receive final approval for gViread
Havells to set up a manufacturing unit in Rajasthan for an investment of Rs360cr
DLF is looking to launch QIP of shares by April, 2018
Idea Cellular seeks government approval for raising FDI limit to 100%

Avenue Supermarts Ltd (DMart), up 5% after announcing Q3FY18 results, PAT up 65.8% yoy
DMart rallies 5% after announcing Q3FY18 results. In Q3FY18, its revenue grew by 22.6% yoy to Rs4, 095cr. EBITDA came in at Rs422cr, up 46.3% yoy . EBITDA margin expanded by 167bps yoy to 12.3% due to an improvement in sales mix and efficiency of centralized procurement. Adjusted PAT increased by 65.8% yoy to Rs252cr.
Board has also approved acquisition of 50.8% paid-up share capital of Avenue E-Commerce Limited for Rs49.2cr. Post-acquisition it will become wholly owned subsidiary. Heavy discounts to attract price sensitive customers and losses of the e-commerce entity will offset the margin gains.

Cipla, Aurobindo and Strides Shasun receive final approval for gViread
Cipla, Aurobindo and Strides Shasun have received final approval for their Abbreviated New Drug Application (ANDA) for Tenofovir Disoproxil Fumarate Tablets, 300mg, from the USFDA. This is a generic version of Gilead Sciences' Viread Tablets, 300mg which is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adults. The final approval means that product is available for immediate commercialization in the US.
Viread 300mg tablets had annual US sales of approximately $725-750mn as per IMS Health. An orange book search on USFDA website indicates that Aurobindo, Cipla, Teva, Macleods Pharmaceuticals and Strides Shasun, all have received approval for this drug on January 26, 2018. Approval for five different filers on the same day is likely to see competition for the Viread 300mg tablets.

Havells to set up a manufacturing unit in Rajasthan for an investment of Rs360cr
Havells is setting-up a new facility at Ghiloth, Neemrana, Rajasthan to manufacture consumer durables, as per the BSE filing. The total estimated cost for the project is Rs360cr (ex-land cost, as the company already owns the land), spread over a period of 3 years. The total investment will be funded through a mix of internal accruals and borrowings. Company expects to start the production from Q3FY19E.
For this investment, the company will be entitled to investment subsidy under the M-SIPS (Modified Special Incentive Package Scheme) introduced by MEITY and also for various tax/ levies and other benefits from the State Government of Rajasthan.

DLF is looking to launch QIP of shares by April, 2018
DLF is looking to launch its qualified institutional placement (QIP) of shares by April 2018, according to a media report.
DLF has already received approval from shareholders to sell 173-million equity shares, which will be determined by the formula laid down by the market regulator Securities and Exchange Board of India. The company may raise Rs4500-5000cr from the QIP.

Idea Cellular seeks government approval for raising FDI limit to 100%
Telecom operator Idea Cellular has made an application to the DIPP (Department of Industrial Policy and Promotion) for raising the FDI limit in Idea to 100%. Foreign investors holdings in Idea Cellular stood at ~27% stake as on December 2017. While 100% FDI is allowed in telecom companies, investments under the automatic route are allowed up to 49%.
At present, Idea Cellular is in the process of merging its telecom business with the Indian unit of Vodafone. As per latest industry data from Trai, Idea and Vodafone jointly have 40.5cr mobile subscribers. This would potentially give the joint entity the largest subscriber base in the Indian telecom segment. Vodafone is expected to hold around 47.5% stake in the merged entity and rest will be owned by Idea and its promoter Aditya Birla Group.

MCX Tips,  Intraday Stock Tips ,  Equity Tips  , Free Trading Tips , Sebi Regsitred Advisory Company , Capitalstars Video Gallery

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.

CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

Capitalstars Updates: News that mattered during the week: 20 Jan 2018

Important news that made headlines during the week.

• Biocon enters into a global partnership with Sandoz to develop, manufacture and commercialize multiple biosimilars in immunology and oncology
• Torrent Pharma acquires US-based generic pharmaceuticals Bio-Pharma Inc
• Tech Mahindra to acquire 17.5% shares of Altiostar on a fully diluted basis
• TCS expands partnership with Shure Inc to establish global development center
• Housing Finance gets RBI nod for US $500mn masala bonds
• Adani Power gets 49% stake in 600 MW Korba West Power
• Varun Beverages to acquire franchisee rights for Pepsico India in the state of Bihar
• Sun Pharma got a license to sell the generic version of Linzess in the US from February 1, 2031, after settling patent litigation
• GAIL, Gazprom sign pact for re-negotiated long-term LNG sale
• Texmaco Rail considering setting up logistics hub and food park in West Bengal
• Kotak Mahindra is mulling divesting its stake in MCX
• Bajaj Finance to hold 12.6% stake in Mobikwik on a fully diluted basis post-conversion of Compulsorily Convertible Preference Shares for a total investment of Rs225cr

MCX Tips,  Intraday Stock Tips ,  Equity Tips  , Free Trading Tips , Sebi Regsitred Advisory Company , Capitalstars Video Gallery

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647

BEST CALL OF THE DAY (FINAL TG ) - 11 APR 2017

BEST CALL OF THE DAY (FINAL TG )

Ø  FUTURES INTRADAY:

Ø  BUY CEAT FUT BUY  CALL 3^RD TG

Ø  PREMIUM FUTURES:

Ø  BUY CEAT FUT BUY  CALL 3^RD TG

Ø  OPTION

Ø  BUY ITC 280 CALL  APRIL BUY CALL3RD  TG

Ø  OPTION PREMIUM:

Ø  BUY CEAT LTD 1350 CALL APRIL BUY CALL 3^RD TG

Ø  BUY CEAT LTD 1350 CALL APRIL BUY CALL 3^RD TG

Ø  STOCK SUPER PREMIUM

Ø  BUY CEAT LTD  BUY CALL 3^RD TG

Ø  EQUITY KING CALL

Ø  MRF FUTURE MADE HIGH 62470 NR FINAL TGT IS 62600

Ø  HNI CASH CALL

Ø  BUY APOLLOTYRE BUY CALL 3^RD TG

Get real time advice for  Intraday Trading Tips , Intraday Market Tips , Stock Trading tips , Free Intraday Tips , Best Accurate Stock Tips  , Equity Tips  and all Maket Updates From Capitalstars .

Investment & trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
CapitalStars Investment Adviser: SEBI Registration Number: INA000001647